Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Abingdon Health PLC ( (GB:ABDX) ) is now available.
Abingdon Health has secured approximately £4.8m of contracts from a US-based customer to develop and scale up several multiplex quantitative lateral flow assay systems that can measure multiple biomarkers in human samples. The 27‑month programme, which begins immediately, includes full programme management, regulatory process management, and analytical and clinical performance services delivered via milestone-based work packages with potential for expanded scope.
The work will utilise Abingdon’s facilities in York and Madison and draw on its regulatory units CS Lifesciences and IVDeology, as well as Abingdon Analytical in Doncaster for analytical and performance evaluation services. These wins reinforce the company’s positioning as an integrated CDMO/CRO “go-to” provider for end-to-end lateral flow test development and manufacturing, strengthening its commercial pipeline and validating its comprehensive service offering to global med-tech customers.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Spark’s Take on ABDX Stock
According to Spark, TipRanks’ AI Analyst, ABDX is a Neutral.
Abingdon Health PLC’s overall stock score is primarily influenced by its mixed financial performance, with strong revenue growth overshadowed by profitability and cash flow challenges. The technical analysis indicates a neutral trend, lacking strong momentum. The valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a moderate overall score.
To see Spark’s full report on ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a UK-headquartered med-tech contract service provider specialising in rapid diagnostic tests and medical technology. The Group operates as a CDMO, offering lateral flow assay development, regulatory support, technology transfer and manufacturing, serving sectors such as infectious disease, clinical and companion diagnostics, animal health and environmental testing across international markets.
Average Trading Volume: 180,568
Technical Sentiment Signal: Buy
Current Market Cap: £18.2M
Learn more about ABDX stock on TipRanks’ Stock Analysis page.